Viatris Gains FDA NDA Acceptance for Fast-Acting Meloxicam in Moderate-to-Severe Acute Pain

A PDUFA goal date of December 27, 2026 now anchors Viatris's regulatory timeline for MR-107A-02, its fast-acting meloxicam candidate, after the FDA accepted the NDA for review for moderate-to-severe acute pain. For regulatory affairs leads tracking the non-opioid analgesic pipeline, the acceptance signals that the agency found the submission sufficiently complete to proceed, a meaningful threshold given the complexity of post-surgical pain trial designs.

The NDA is supported by two randomized, double-blind, placebo- and active-controlled Phase 3 trials, one in herniorrhaphy patients (NCT06215859, n=579) and one in bunionectomy patients (NCT06215820, n=410). Both trials used Sum of Pain Intensity Difference over 0–48 hours (SPID0-48h) as the primary endpoint, with tramadol 50 mg q6h as an active comparator to validate model sensitivity. Both met primary and secondary endpoints.

Beyond analgesic efficacy, both trials tracked opioid rescue medication usage, measuring mean doses consumed and the proportion of opioid-free patients across combined inpatient and outpatient phases. Fast-acting meloxicam demonstrated a reduction in opioid usage in both studies, a data point that carries weight as payers and health systems continue to scrutinize opioid prescribing patterns in post-surgical settings. The safety profile was consistent with the established COX-inhibitor mechanism of action.

Viatris positions MR-107A-02 within a broader lifecycle optimization strategy that includes new formulations, delivery technologies, and indication expansions, a value-added medicines approach that regulatory teams will recognize as distinct from standard generic development. The Phase 3 data were presented at PAINWeek 2025, providing a public scientific record ahead of the agency's formal review cycle.

Acute pain affects more than 80 million individuals in the United States annually and remains a primary driver of emergency department visits and postoperative morbidity; opioids continue to be a commonly used first-line treatment in that setting, which frames the regulatory and public health context the agency will weigh at the PDUFA date.

The December 2026 action date gives Viatris and its regulatory counterparts approximately seven months to respond to any agency information requests and prepare for a potential approval decision that would introduce a non-opioid oral option into a market where prescribing alternatives remain limited.

Source: Viatris Inc. via PR Newswire, May 18, 2026.